OBJECTIVE: Adiponectin, an adipokine secreted by the adipocyte, is inversely related to adiposity and directly related to insulin sensitivity. In type 1 diabetes mellitus (T1DM), however, data thus far are contradictory. We investigated the relationship between adiponectin and exercise inT1DM. METHODS: Forty-nine children (14.5 +/- 2.0 yr, range 8-17 yr) with T1DM on an insulin pump were studied during two 75-min exercise sessions with and without continuation of the basal rate within 4 wk. Adiponectin and epinephrine concentrations were measured before and during exercise. RESULTS: Mean preexercise adiponectin concentration was 11.2 +/- 4.7 mg/L (range 2.7-23.0 mg/L) with a mean absolute difference of 1.7 mg/L between the 2 d. Adiponectin concentrations did not change meaningfully during exercise (mean change: -0.1 +/- 1.2 mg/L; p = 0.17). Adiponectin correlated inversely with body mass index percentile (p = 0.02) but not with age, gender, duration of diabetes, hemoglobin A1c, or preexercise glucose. However, those with higher baseline adiponectin concentrations were less likely to become hypoglycemic during exercise, 36% becoming hypoglycemic when baseline adiponectin concentration was <10 mg/L, 42% when 10 to <15 mg/L, and 15% when > or =15 mg/L (p = 0.02). Baseline epinephrine concentrations were not associated with adiponectin, and in those whose nadir glucose was < or =100 mg/dL, there was no correlation between epinephrine response and adiponectin (p = 0.16). CONCLUSIONS: Adiponectin concentrations are stable from day to day, are not affected by acute exercise or metabolic control, and vary inversely with adiposity. Higher adiponectin concentration appears to be associated with a decrease in hypoglycemia risk during exercise. Further studies are needed to examine whether adiponectin protects against exercise-induced hypoglycemia by directly enhancing the oxidation of alternate fuels.
OBJECTIVE:Adiponectin, an adipokine secreted by the adipocyte, is inversely related to adiposity and directly related to insulin sensitivity. In type 1 diabetes mellitus (T1DM), however, data thus far are contradictory. We investigated the relationship between adiponectin and exercise inT1DM. METHODS: Forty-nine children (14.5 +/- 2.0 yr, range 8-17 yr) with T1DM on an insulin pump were studied during two 75-min exercise sessions with and without continuation of the basal rate within 4 wk. Adiponectin and epinephrine concentrations were measured before and during exercise. RESULTS: Mean preexercise adiponectin concentration was 11.2 +/- 4.7 mg/L (range 2.7-23.0 mg/L) with a mean absolute difference of 1.7 mg/L between the 2 d. Adiponectin concentrations did not change meaningfully during exercise (mean change: -0.1 +/- 1.2 mg/L; p = 0.17). Adiponectin correlated inversely with body mass index percentile (p = 0.02) but not with age, gender, duration of diabetes, hemoglobin A1c, or preexercise glucose. However, those with higher baseline adiponectin concentrations were less likely to become hypoglycemic during exercise, 36% becoming hypoglycemic when baseline adiponectin concentration was <10 mg/L, 42% when 10 to <15 mg/L, and 15% when > or =15 mg/L (p = 0.02). Baseline epinephrine concentrations were not associated with adiponectin, and in those whose nadir glucose was < or =100 mg/dL, there was no correlation between epinephrine response and adiponectin (p = 0.16). CONCLUSIONS:Adiponectin concentrations are stable from day to day, are not affected by acute exercise or metabolic control, and vary inversely with adiposity. Higher adiponectin concentration appears to be associated with a decrease in hypoglycemia risk during exercise. Further studies are needed to examine whether adiponectin protects against exercise-induced hypoglycemia by directly enhancing the oxidation of alternate fuels.
Authors: T Costacou; J C Zgibor; R W Evans; J Otvos; M F Lopes-Virella; R P Tracy; T J Orchard Journal: Diabetologia Date: 2004-12-23 Impact factor: 10.122
Authors: Philip W Peake; Adamandia D Kriketos; Lesley V Campbell; Yvonne Shen; John A Charlesworth Journal: Eur J Endocrinol Date: 2005-09 Impact factor: 6.664
Authors: Markku Saraheimo; Carol Forsblom; Johan Fagerudd; Anna-Maija Teppo; Kim Pettersson-Fernholm; Jan Frystyk; Allan Flyvbjerg; Per-Henrik Groop Journal: Diabetes Care Date: 2005-06 Impact factor: 19.112
Authors: Eva Tsalikian; Craig Kollman; William B Tamborlane; Roy W Beck; Rosanna Fiallo-Scharer; Larry Fox; Kathleen F Janz; Katrina J Ruedy; Darrell Wilson; Dongyuan Xing; Stuart A Weinzimer Journal: Diabetes Care Date: 2006-10 Impact factor: 19.112
Authors: David M Maahs; Lorraine G Ogden; Gregory L Kinney; Paul Wadwa; Janet K Snell-Bergeon; Dana Dabelea; John E Hokanson; James Ehrlich; Robert H Eckel; Marian Rewers Journal: Circulation Date: 2005-02-07 Impact factor: 29.690
Authors: A Schäffler; H Herfarth; G Paul; A Ehling; U Müller-Ladner; J Schölmerich; B Zietz Journal: Exp Clin Endocrinol Diabetes Date: 2004-07 Impact factor: 2.949